Renal Cell Carcinoma in End-Stage Renal Disease: A Retrospective Study in Patients from Hungary.


Journal

Pathobiology : journal of immunopathology, molecular and cellular biology
ISSN: 1423-0291
Titre abrégé: Pathobiology
Pays: Switzerland
ID NLM: 9007504

Informations de publication

Date de publication:
2023
Historique:
received: 28 09 2022
accepted: 14 01 2023
medline: 1 11 2023
pubmed: 26 1 2023
entrez: 25 1 2023
Statut: ppublish

Résumé

End-stage renal disease (ESRD) and acquired cystic kidney disease (ACKD) are known risk factors for renal cell carcinoma (RCC). Hereby, the clinicopathological features of RCCs developed in ESRD were investigated. A database consisting of 34 tumors from 31 patients with ESRD among 2,566 nephrectomy samples of RCC was built. The demographic, clinical, and follow-up data along with pathological parameters were analyzed. The RCCs were diagnosed according to the current WHO Classification of Urinary and Male Genital Tumors. Twenty-two tumors developed in men and 12 in women, with a median age of 56 years (range: 27-75 years). The causes of ESRD were glomerulonephritis (n = 7), hypertensive kidney disease (n = 6), autosomal dominant polycystic kidney disease (n = 6), chronic pyelonephritis (n = 4), diabetic nephropathy (n = 3), chemotherapy-induced nephropathy (n = 1), and undetermined (n = 4). ACKD complicated ESRD in 12 patients. The following histological subtypes were identified: clear cell RCC (n = 19), papillary RCC (n = 5), clear cell papillary tumor (n = 5), ACKD RCC (n = 3), and eosinophilic solid and cystic RCC (n = 2). The median tumor size was 31 mm (range: 10-80 mm), and 32 tumors were confined to the kidney (pT1-pT2). There was no tumor-specific death during the period of this study. Progression was registered in 1 patient. In our cohort, the most common RCC subtype was clear cell RCC (55%), with a frequency that exceeded international data appreciably (14-25%). The incidence of clear cell papillary tumor and ACKD RCC (14.7% and 8.5%) was lower than data reported in the literature (30% and 40%). Our results indicate a favorable prognosis of RCC in ESRD.

Identifiants

pubmed: 36696889
pii: 000529276
doi: 10.1159/000529276
pmc: PMC10614572
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

322-332

Informations de copyright

© 2023 The Author(s). Published by S. Karger AG, Basel.

Références

Eur Urol. 2011 Aug;60(2):366-73
pubmed: 21377780
Pathol Int. 2018 Oct;68(10):543-549
pubmed: 30187581
Am J Surg Pathol. 2013 Oct;37(10):1469-89
pubmed: 24025519
Pathol Oncol Res. 2017 Jul;23(3):689-698
pubmed: 28032311
Pathol Oncol Res. 2020 Jul;26(3):1767-1776
pubmed: 31656019
Am J Surg Pathol. 2005 Apr;29(4):443-51
pubmed: 15767796
Virchows Arch. 2018 Dec;473(6):725-738
pubmed: 30232607
Mod Pathol. 2006 Jun;19(6):780-7
pubmed: 16575398
Int J Urol. 2018 Sep;25(9):780-786
pubmed: 30066367
Cancer Med. 2016 Aug;5(8):2101-8
pubmed: 27228559
Med Mol Morphol. 2010 Dec;43(4):231-4
pubmed: 21267700
Nephrol Dial Transplant. 1995;10(5):593-6
pubmed: 7566566
Am J Surg Pathol. 2018 Oct;42(10):1396-1401
pubmed: 30001236
Hum Pathol. 2021 Oct;116:1-11
pubmed: 34153307
Int J Surg Pathol. 2012 Feb;20(1):19-28
pubmed: 21791489
Am Health Drug Benefits. 2018 May;11(3):118-127
pubmed: 29910844
Histopathology. 2019 Aug;75(2):174-184
pubmed: 30895640
Pathology. 2021 Oct;53(6):720-727
pubmed: 33947521
Nephrol Dial Transplant. 2011 May;26(5):1677-82
pubmed: 20864552
Am J Nephrol. 2021;52(2):98-107
pubmed: 33752206
Abdom Imaging. 1995 Nov-Dec;20(6):569-71
pubmed: 8580756
Hum Pathol. 2014 Jan;45(1):59-64
pubmed: 24182559
Am J Surg Pathol. 2006 Feb;30(2):141-53
pubmed: 16434887
Kidney Int. 2002 Jun;61(6):2201-9
pubmed: 12028461
Int Braz J Urol. 2011 Jan-Feb;37(1):29-32;discussion 33-4
pubmed: 21385477
Cancer Sci. 2012 Mar;103(3):569-76
pubmed: 22145865
Ann Diagn Pathol. 2000 Oct;4(5):311-5
pubmed: 11073338
Am J Surg Pathol. 2016 Jan;40(1):60-71
pubmed: 26414221
Biomedicines. 2022 Mar 11;10(3):
pubmed: 35327459
Medicine (Baltimore). 1990 Jul;69(4):217-26
pubmed: 2374506
Am J Surg Pathol. 2014 Nov;38(11):1457-67
pubmed: 25093518
Urology. 1994 Oct;44(4):497-501
pubmed: 7941189
Am J Surg Pathol. 2018 Sep;42(9):1156-1165
pubmed: 29851703
Am J Surg Pathol. 2015 Jul;39(7):873-88
pubmed: 25970682
Am J Surg Pathol. 2013 Oct;37(10):1490-504
pubmed: 24025520
Biomedicines. 2022 Jan 29;10(2):
pubmed: 35203531
BMJ Clin Evid. 2010 Jul 19;2010:
pubmed: 21418665
Eur Urol. 2018 Oct;74(4):487-488
pubmed: 30029819
J Am Soc Nephrol. 2019 Jan;30(1):127-135
pubmed: 30559143
Lancet. 1999 Jul 10;354(9173):93-9
pubmed: 10408483
Hum Pathol. 2021 Aug;114:9-18
pubmed: 33961838
Arch Pathol Lab Med. 2003 Feb;127(2):E89-92
pubmed: 12562261
Am J Surg Pathol. 2015 Jul;39(7):889-901
pubmed: 25970683
Eur Urol. 2018 Oct;74(4):483-486
pubmed: 29941307

Auteurs

Dávid Semjén (D)

Department of Pathology, Medical School and Clinical Centre, University of Pécs, Pécs, Hungary.

Borbála Dénes (B)

MedServ Ltd., Budapest, Hungary.

Áron Somorácz (Á)

MedServ Ltd., Budapest, Hungary.

Attila Fintha (A)

Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.

Gertrúd Forika (G)

Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.

Alex Jenei (A)

Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.

Deján Dobi (D)

Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary.

Tamás Micsik (T)

Pathology Unit, Fejér County Szent György University Teaching Hospital, Székesfehérvár, Hungary.

Kornélia Veronika Eizler (KV)

Pathology Unit, Fejér County Szent György University Teaching Hospital, Székesfehérvár, Hungary.

Nándor Giba (N)

Pathology Unit, Fejér County Szent György University Teaching Hospital, Székesfehérvár, Hungary.

Fanni Sánta (F)

Department of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.

Anita Sejben (A)

Department of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.

Béla Iványi (B)

Department of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.

Levente Kuthi (L)

Department of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH